Headquartered in San Carlos, CA Fiscal year ends December NASDAQ: PCVX vaxcyte.com
Vaxcyte, Inc. is a clinical-stage vaccine company with no product revenue. It develops vaccines designed to protect against bacterial diseases.
Its lead program is VAX-31, a 31-valent pneumococcal conjugate vaccine candidate for preventing invasive pneumococcal disease and pneumococcal pneumonia. VAX-31 is in the OPUS Phase 3 adult program, where the pivotal OPUS-1 trial reported positive topline data in October 2026. It is also in a Phase 2 infant dose-finding study. The company plans a BLA submission for the adult indication in the first half of 2028.
The broader PCV franchise includes:
- VAX-24, a 24-valent candidate with positive Phase 2 data in adults and infants;
- VAX-XL, an earlier-stage broader-spectrum candidate.
These candidates are positioned against marketed PCVs such as Prevnar 20 and Capvaxive. They rely on the company's carrier-sparing, site-specific conjugation technology and on XpressCF, a cell-free protein synthesis platform exclusively licensed from Sutro Biopharma.
Other pipeline candidates include VAX-A1, a Group A Streptococcus vaccine in a Phase 1 study in Australian adults, and VAX-GI, a Shigella vaccine candidate.
Vaxcyte is funded through equity and debt offerings, most recently about $1.1 billion in net proceeds in October 2026. It is investing heavily in manufacturing scale-up and supply chain ahead of a potential U.S. commercial launch. Updated
A pro forma cash pile of roughly $3.4 billion funds Vaxcyte all the way to a potential US launch of VAX-31, which just met every primary endpoint in the pivotal OPUS-1 Phase 3. The loss narrowed against expectations even as R&D climbed on manufacturing scale. FDA scrutiny of serotypes 3 and 12F remains the open question.
Retail investors who spotted Seth Klarman buying Vaxcyte in May were already two months behind a trade Baupost had quietly begun unwinding. Understanding exactly what got lost in that gap changes how…
Market pullbacks can make nervous investors leery of investing in industries that are more speculative. Wall Street still has big expectations for Viking Therapeutics.
2020 will forever be remembered as the year the coronavirus pandemic broke out. But in the year of the lockdowns, there were also 480 initial public offerings on the U.S. stock market…
Vaxcyte, Inc. is a clinical-stage vaccine company with no product revenue. It develops vaccines designed to protect against bacterial diseases.
The Wall Street consensus 12-month price target for PCVX is $117.30. PCVX price prediction →
